BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tan Y, Xu Q, Wu Z, Zhang W, Li B, Zhang B, Xu X, Zhang B, Yan K, Song J, Lv T, Yang J, Jiang L, Shi Y, Yang J, Yan L. Overexpression of PD-L1 is an Independent Predictor for Recurrence in HCC Patients Who Receive Sorafenib Treatment After Surgical Resection. Front Oncol 2022;11:783335. [DOI: 10.3389/fonc.2021.783335] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Song C, Zhang J, Wen R, Li Q, Zhou J, Xiaoli Liu, Wu Z, Lv Y, Wu R. Improved anti-hepatocellular carcinoma effect by enhanced Co-delivery of Tim-3 siRNA and sorafenib via multiple pH triggered drug-eluting nanoparticles. Mater Today Bio 2022;16:100350. [PMID: 35856043 DOI: 10.1016/j.mtbio.2022.100350] [Reference Citation Analysis]
2 Testa U, Pelosi E, Castelli G. Clinical value of identifying genes that inhibit hepatocellular carcinomas. Expert Rev Mol Diagn 2022;22:1009-35. [PMID: 36459631 DOI: 10.1080/14737159.2022.2154658] [Reference Citation Analysis]